Back to Journals

Blood and Lymphatic Cancer: Targets and Therapy


Professor Dingli

Hematology and Internal Medicine, Mayo Clinic, United States

Professor Dingli

Editor-in-Chief: David Dingli

Dr Dingli is an associate professor of Medicine at Mayo Clinic where he has a joint appointment between the Division of Hematology and the Department of Molecular Medicine. He is also an adjunct professor within the Biomedical Informatics and Computational Biology (BICB) Program at the University of Minnesota, Rochester. His hematology training has taken him to the University of Glasgow Hospitals and then Mayo Clinic. For his PhD thesis, he researched the use of replication competent measles viruses for therapy of multiple myeloma. He has generated a recombinant virus that can be non-invasively tracked in vivo using molecular imaging strategies. This vector is now in clinical trials in patients with advanced myeloma. His clinical practice is devoted to patients with plasma cell disorders and chronic myeloid leukemia.

Dr Dingli’s research also includes the use of mathematical and computational models to understand tumor development and evolution, hematopoietic stem cell dynamics, and hematopoiesis as well as therapy of hematopoietic tumors with recombinant viruses and other novel agents. He trained in mathematical biology at Mayo Clinic, the University of Tennessee (Knoxville), the Santa Fe Institute, and the Program for Evolutionary Dynamics at Harvard University where he was a Mayo Clinic Scholar for two years.  He has applied mathematical and computational modeling to a variety of disorders including multiple myeloma, chronic myeloid leukemia, paroxysmal nocturnal hemoglobinuria, and cyclic hematopoiesis. 

On a national and international level, Dr Dingli is on the editorial advisory board of several journals and serves as a reviewer for many journals. He is also a reviewer for numerous funding agencies in the United States and Europe.


Editorial Board

Federico Caligaris-Cappio, Professor of Internal Medicine, Chair of Internal Medicine and Head, Division of Internal Medicine; Head, Department of Oncology, Università Vita-Salute San Raffaele, Milano, Italy

Preet M Chaudhary, Professor, Department of Medicine, Ron Bloom Endowed Chair in Lymphoma, University of Southern California; Chief, Jane Ann Nohl Division of Hematology and Center for the Study of Blood Diseases, Los Angeles, CA, USA

Bruce D. Cheson, Professor of Medicine, Head of Hematology, Deputy Chief, Division of Hematology-Oncology Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington DC, WA, USA

Wenya Huang, Professor, Department of Medical Laboratory Science and Biotechnology, National Cheng Kung University Medical College, Tainan; Consultant, Molecular Diagnosis, Pathology, National Cheng Kung University Hospital, Tainan, Taiwan

Joseph McGuirk, Professor of Medicine, Schutte-Speas Professor of Hematology-Oncology; Division Director, Hematologic Malignancies and Cellular Therapeutics; Medical Director, Blood and Marrow Transplant, Department of Internal Medicine, The University of Kansas Health System, Cancer Center and Medical Pavilion, Westwood, KS, USA

Mariano Provencio, Professor of Medicine, Oncology Department, Hospital Universitario Puerta de Hierro, University of Madrid, Madrid, Spain

Giuseppe Saglio, Professor of Hematology, University of Turin; Director of the Department of Clinical and Biological Sciences of the University of Torino; Director, Hematology Division, Ospedale Mauriziano, Torino, Italy

SM Singh, Professor & Coordinator, Tumor Immunology, Faculty of Science, School of Biotechnology, Banaras Hindu University, Varanasi, India

Masaki Yasukawa, Professor and Chairman, Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine; Chief of Center, Reproductive Medicine, Ehime University, Toon, Ehime, Japan

Zhao Jinhua, Professor, Director, Dept. of Nuclear Medicine, The First People's Hospital, Shanghai Jiaotong University, Shanghai, People's Republic of China